BioSpace News Archive

Industrial Partnership between NTT Research and the Simons Institute for the Theory of Computing Provides Framework for Collaboration

Boston Scientific Corporation announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company’s shelf registration statement.

Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian and pancreatic cancers, respectively.

OraSure Technologies, Inc., a leader in point-of-care diagnostic tests and specimen collection devices, announced its financial results for the three and nine months ended September 30, 2019.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended September 30, 2019.

Prioritizing U.S. Investigational Device Exemption (IDE) submission for use of the LungFit™ system in bronchiolitis (BRO) to facilitate completion of the pivotal LungFit™ BRO study in winter 2020/21

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter 2019 financial results and corporate highlights.

Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.

Call will feature data from DURECT’s late-breaking oral presentation at the 2019 Liver Meeting®

Quotient Limited, a commercial-stage diagnostics company, announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per share.